Proving the Business Case for the Internet of Things

Mobile health apps provide baffling choice for consumers, says IMS

Steve Rogerson
September 22, 2015
The number of mobile health applications available to consumers now surpasses 165,000, as developers incorporate innovative data collection features linked to sensors and wearables, according to a report by the IMS Institute for Healthcare Informatics.
While most available apps focus on overall wellness, healthcare systems and professionals are expressing greater interest and excitement in broader app use as barriers to mainstream adoption of mhealth are removed, especially in the area of chronic disease management.
The study from the Connecticut-based institute found that one in ten apps now has the capability to connect to a device or sensor, providing biofeedback and physiological function data from the patient and greatly extending the accuracy and convenience of data collection. Nearly a quarter of consumer apps are now focused on disease and treatment management, while two-thirds target fitness and wellness. The number and variety of mhealth apps present an overwhelming set of options for consumers, resulting in 40 per cent of apps having fewer than 5000 downloads.
The study extends the institute’s examination of consumer-focused mobile apps in the health system conducted in 2013. Researchers drew on IMS Health’s proprietary AppScript Score database and analysis of 26,864 apps available in the US Apple iTunes and Android app stores – a representative sample of the most widely used mhealth apps by consumers. As part of the study, the institute also conducted structured interviews with health- and technology-focused thought leaders and executives on the role and status of healthcare apps.
“While much progress has been made over the past two years, mhealth apps are still far from being a fully integrated component of healthcare delivery,” said Murray Aitken, executive director of the IMS Institute for Healthcare Informatics. “Healthcare providers are actively addressing the remaining barriers. These include developing and adopting trusted platforms for on-going apps curation and evaluation, creating practical reimbursement models, and ensuring true interoperability within and across healthcare systems.”
In addition to improved user data collection capability, during the past two years, the percentage of mhealth apps with the capability to connect to social networks increased from 26 to 34 per cent, underscoring the importance of social networking in consumer engagement. Less progress has been made in enabling apps to connect and communicate with provider healthcare systems – a fundamental requirement for mhealth to realise its full value in healthcare management.
The total number of available mhealth apps is growing rapidly, including a 106 per cent increase in the number of health-related Apple iOS apps since 2013. This can present an intimidating choice for consumers, leading some simply to select the most popular app and others to try multiple apps in an effort to determine what is best for them.
The study found that just 12 per cent of mhealth apps accounted for more than 90 per cent of all consumer downloads, with nearly half of all downloads generated by just 36 apps. Physicians also struggle with the number of apps available and the limited mechanisms for assessing accuracy, efficacy and appropriateness for their patients.
Platforms for rating, evaluating and, in some cases, certifying apps are becoming available to providers, enabling them to prescribe apps more confidently as part of disease prevention and treatment protocols. Moreover, 30-day retention rates for mhealth apps prescribed by a healthcare professional are ten per cent higher than those self-selected by patients. For prescribed fitness apps, the retention rate is 30 per cent higher.
Most research studies to date focus on app usage rather than their effectiveness in improving patient outcomes or lowering healthcare costs. However, momentum is building for observational studies and randomised clinical trials that will yield evidence to support the value of apps, specifically in the areas of type-two diabetes, cardiovascular disease, obesity and mental health. The number of clinical trials using mobile apps has more than doubled in the past two years, rising from 135 to 300.
The majority of trials underway are interventional, underscoring the importance of providing rigorous study results to physicians in need of evidence that supports integration of apps in their treatment protocols. Demand has increased for larger clinical trials in an effort to examine better sub-populations of app users. Of the large mhealth app clinical trials that recruit patients, 53 per cent are directed at the senior population – a key demographic that requires healthcare management and is targeted for increased app use.
Among healthcare providers interviewed by the IMS Institute, most are confident that mhealth can improve overall outcomes, reduce the cost of healthcare and encourage patients to take a more active role in improving their health. Providers emphasised that mhealth data integrated with electronic healthcare records are critical to better clinical decision making and patient communications.
With the universal enthusiasm expressed for mhealth, providers urged stakeholders to address remaining barriers, including: limited connectivity and integration into workflow systems; a slow paradigm shift in reimbursement processes and delivery of care; data confidentiality, privacy, security and regulatory uncertainties; lack of scientific evidence to measure the efficacy of apps; and the inability to reach the most vulnerable cohorts of patients, mainly the elderly or non-English speaking.
The IMS Institute for Healthcare Informatics provides key policy setters and decision makers in the global health sector with insights into healthcare dynamics derived from granular analysis of information. It is a research-driven entity with a worldwide reach that collaborates with external healthcare experts from across academia and the public and private sectors to apply objectively IMS Health’s proprietary global information and analytical assets.